Your browser doesn't support javascript.
loading
Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa, Yuki; Imamura, Michio; Yamauchi, Masami; Hayes, C Nelson; Aikata, Hiroshi; Okamoto, Wataru; Miyata, Yoshihiro; Okada, Morihito; Hattori, Noboru; Sugiyama, Kazuhiko; Yoshioka, Yukio; Toratani, Shigeaki; Takechi, Masaaki; Ichinohe, Tatsuo; Ueda, Tsutomu; Takeno, Sachio; Kobayashi, Tsuyoshi; Ohdan, Hideki; Teishima, Jun; Hide, Michihiro; Nagata, Yasushi; Kudo, Yoshiki; Iida, Koji; Chayama, Kazuaki.
  • Yoshikawa Y; Department of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Imamura M; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
  • Yamauchi M; Department of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. mimamura@hiroshima-u.ac.jp.
  • Hayes CN; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan. mimamura@hiroshima-u.ac.jp.
  • Aikata H; Department of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Okamoto W; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
  • Miyata Y; Department of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Okada M; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
  • Hattori N; Department of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Sugiyama K; Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
  • Yoshioka Y; Cancer Treatment Center, Hiroshima University Hospital, Hiroshima, Japan.
  • Toratani S; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
  • Takechi M; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
  • Ichinohe T; Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Ueda T; Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
  • Takeno S; Department of Molecular Oral Medicine and Maxillofacial Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Kobayashi T; Department of Molecular Oral Medicine and Maxillofacial Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Ohdan H; Department of Oral and Maxillofacial Surgery, Program of Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Teishima J; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Hide M; Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Nagata Y; Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Kudo Y; Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Iida K; Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Chayama K; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
BMC Cancer ; 22(1): 1232, 2022 Nov 29.
Article en En | MEDLINE | ID: mdl-36447159
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article